drugset / Trial / NCT03382977
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Timeline
- Start
- 2017-12-06
- Primary completion
- 2025-07-30
- Completion
- 2025-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lomustine | Small molecule | 110 mg/m2 | Oral |
| Subject | VBI-1901 | Unknown | 0.4 ug | Intravenous |
| Subject | VBI-1901 | Unknown | 2 ug | Intravenous |
| Subject | VBI-1901 | Unknown | 10 ug | Intravenous |
| Comparator | carmustine | Small molecule | 150 mg/m2 | Intravenous |